Eris Lifesciences Resultados de beneficios anteriores
Pasado controles de criterios 2/6
Eris Lifesciences ha aumentado sus beneficios a una tasa media anual de 7.1%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento de 14.8% anual. Los ingresos han ido creciendo a una tasa media de 13.6% al año. La rentabilidad financiera de Eris Lifesciences es de 15.6%, y sus márgenes netos son de 21%.
Información clave
7.1%
Tasa de crecimiento de los beneficios
7.3%
Tasa de crecimiento del BPA
Crecimiento de la industria Pharmaceuticals | 17.5% |
Tasa de crecimiento de los ingresos | 13.6% |
Rentabilidad financiera | 15.6% |
Margen neto | 21.0% |
Próxima actualización de resultados | 21 May 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price
May 10An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued
Mar 14Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report
Feb 15Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)
Dec 28Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Dec 07Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Nov 11Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Jul 20Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?
Nov 20These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely
Jun 20A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)
Feb 24Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?
Dec 28Here's Why I Think Eris Lifesciences (NSE:ERIS) Might Deserve Your Attention Today
Sep 23If You Like EPS Growth Then Check Out Eris Lifesciences (NSE:ERIS) Before It's Too Late
May 26Eris Lifesciences Limited (NSE:ERIS) Shares Could Be 34% Above Their Intrinsic Value Estimate
Apr 17Eris Lifesciences Limited's (NSE:ERIS) Stock Has Fared Decently: Is the Market Following Strong Financials?
Mar 12Does Eris Lifesciences (NSE:ERIS) Deserve A Spot On Your Watchlist?
Feb 25Why Eris Lifesciences Limited (NSE:ERIS) Is A Dividend Rockstar
Feb 12Eris Lifesciences Limited (NSE:ERIS) Analysts Are Pretty Bullish On The Stock After Recent Results
Jan 30Read This Before Buying Eris Lifesciences Limited (NSE:ERIS) Shares
Jan 17Our View On Eris Lifesciences' (NSE:ERIS) CEO Pay
Dec 30Is Eris Lifesciences Limited's (NSE:ERIS) Recent Performance Tethered To Its Attractive Financial Prospects?
Dec 10Eris Lifesciences (NSE:ERIS) Shareholders Booked A 25% Gain In The Last Year
Nov 23Is It Worth Buying Eris Lifesciences Limited (NSE:ERIS) For Its 1.1% Dividend Yield?
Oct 22How Does Eris Lifesciences' (NSE:ERIS) CEO Salary Compare to Peers?
Oct 01How Much Are Eris Lifesciences Limited (NSE:ERIS) Insiders Taking Off The Table?
Sep 14Investor Optimism Abounds Eris Lifesciences Limited (NSE:ERIS) But Growth Is Lacking
Aug 22Eris Lifesciences Limited (NSE:ERIS) Looks Interesting, And It's About To Pay A Dividend
Aug 08Should You Buy Eris Lifesciences Limited (NSE:ERIS) For Its Upcoming Dividend?
Aug 08Eris Lifesciences Limited's (NSE:ERIS) Risks Elevated At These Prices
Jul 28Desglose de ingresos y gastos
Cómo gana y gasta dinero Eris Lifesciences. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
---|---|---|---|---|
31 Dec 23 | 18,406 | 3,864 | 3,958 | 0 |
30 Sep 23 | 17,750 | 3,856 | 3,841 | 0 |
30 Jun 23 | 17,298 | 3,824 | 3,721 | 0 |
31 Mar 23 | 16,618 | 3,822 | 3,548 | 0 |
31 Dec 22 | 15,663 | 3,970 | 3,362 | 0 |
30 Sep 22 | 14,766 | 3,959 | 3,104 | 0 |
30 Jun 22 | 13,746 | 3,940 | 2,773 | 0 |
31 Mar 22 | 13,262 | 4,061 | 2,622 | 0 |
31 Dec 21 | 12,993 | 3,941 | 2,572 | 0 |
30 Sep 21 | 12,763 | 3,834 | 2,553 | 0 |
30 Jun 21 | 12,482 | 3,728 | 2,377 | 0 |
31 Mar 21 | 11,926 | 3,551 | 2,439 | 0 |
31 Dec 20 | 11,625 | 3,432 | 2,790 | 0 |
30 Sep 20 | 11,192 | 3,165 | 2,717 | 0 |
30 Jun 20 | 10,744 | 3,015 | 2,156 | 0 |
31 Mar 20 | 10,582 | 2,965 | 2,317 | 0 |
31 Dec 19 | 10,252 | 2,943 | 2,520 | 0 |
30 Sep 19 | 10,119 | 3,110 | 2,470 | 0 |
30 Jun 19 | 9,920 | 3,036 | 1,887 | 0 |
31 Mar 19 | 9,672 | 2,908 | 2,453 | 0 |
31 Dec 18 | 9,851 | 2,925 | 2,304 | 0 |
30 Sep 18 | 9,442 | 2,870 | 2,258 | 0 |
30 Jun 18 | 9,212 | 2,945 | 1,708 | 0 |
31 Mar 18 | 8,196 | 2,941 | 2,027 | 0 |
31 Dec 17 | 8,026 | 2,800 | 1,931 | 0 |
30 Sep 17 | 7,781 | 2,735 | 1,818 | 0 |
30 Jun 17 | 7,277 | 2,505 | 1,787 | 0 |
31 Mar 17 | 7,205 | 2,468 | 1,737 | 0 |
31 Mar 16 | 5,967 | 1,112 | 1,746 | 0 |
31 Mar 15 | 5,456 | 892 | 1,632 | 0 |
31 Mar 14 | 5,088 | 704 | 1,664 | 0 |
Ingresos de calidad: ERIS tiene ganancias de alta calidad.
Margen de beneficios creciente: Los actuales márgenes de beneficio(21%) de ERIS son inferiores a los del año pasado (25.3%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: Los beneficios de ERIS han crecido un 7.1% al año en los últimos 5 años.
Acelerando crecimiento: ERIS ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.
Beneficios vs. Industria: ERIS tuvo un crecimiento negativo de los beneficios (-2.7%) durante el año pasado, lo que dificulta la comparación con la media de la industria Pharmaceuticals (23.8%).
Rentabilidad financiera
Alta ROE: La rentabilidad financiera de ERIS (15.6%) se considera baja.